Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT has specific guidance for use in Scotland1

  • In Scotland, DUPIXENT is accepted for restricted use for severe asthma in patients 12 years and older with blood eosinophils (EOS) ≥150 cells/mL and fraction of exhaled nitric oxide (FeNO) ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies1

 

Scottish Medicines Consortium (SMC) advice1

  • SMC have restricted the use of DUPIXENT to patients with blood EOS ≥150 cells/mL and FeNO ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies
  • SMC reviewed DUPIXENT under the context of its indication: as add-on maintenance treatment for severe asthma in adults and adolescents 12 years and older with Type 2 inflammation characterised by raised blood EOS and/or raised FeNO, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment
  • The SMC advice applies to an approved Patient Access Scheme (PAS) that delivers the cost-effectiveness of DUPIXENT or a PAS/list price that is equivalent or lower

EOS, eosinophils; FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL, interleukin; NHS, National Health Service; PAS, Patient Access Scheme; ppb, parts per billion; SMC, Scottish Medicines Consortium.

References

  1. Scottish Medicines Consortium. Dupilumab (Dupixent). Available at: https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/. Date accessed: May 2021.